Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound, systematically named [2-(1-AMINO-2-HYDROXYPROPYL)-2-HYDROXY-4-ISOBUTYL-5-OXO-2,5-DIHYDRO-1H-IMIDAZOL-1-YL]ACETALDEHYDE, is an experimental chemical component identified in the Protein Data Bank (PDB) under the code CR0 and listed in DrugBank with ID DB02488. It is also known by the longer synonym "1-(2-Ethanone)-2-Hydroxy-2-(1-Amino-2-Methyl-2-Ethanol)-4-(2-Dimethyl)Ethane-Imidazoline-5-One;Chromophore (Thr-Leu-Gly)" and the shorter descriptor "Chromophore (Thr-Leu-Gly)". With a molecular formula of C12 H21 N3 O5 and a molecular weight of 287.312, it is classified as an L-PEPTIDE LINKING type, suggesting a potential role in peptide modification or as a component incorporating peptide-like structures. Its specific mechanism of action and primary indications are not detailed in publicly available information, indicating its status as a research or experimental compound rather than a developed pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [2-(1-AMINO-2-HYDROXYPROPYL)-2-HYDROXY-4-ISOBUTYL-5-OXO-2,5-DIHYDRO-1H-IMIDAZOL-1-YL]ACETALDEHYDE.